2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-
Fanconi Anemia
Children's Hospital Medical Center, CincinnatiSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Fanconi Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Porteus, Matthew, MD | Phase 2/3 | BBB |
Fludarabine Porteus, Matthew, MD | Phase 2/3 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BBB |
FILGRASTIM Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BBB |
View all 44 →
Same molecule, other indications
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →